# Empagliflozin in Hypertrophic Cardiomyopathy

> **NCT05182658** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Cardiology, Warsaw, Poland** · enrollment: 250 (estimated)

## Conditions studied

- Hypertrophic Cardiomyopathy
- Heart Failure

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05182658
- **Lead sponsor:** National Institute of Cardiology, Warsaw, Poland
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05182658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05182658, "Empagliflozin in Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05182658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*